

General Rules & Quality Standards

Quality Improvement and Projects Category

We are keen to ensure that your work is presented in the best possible light and in order to ensure that you have the greatest chance of success please take note of the following general rules and quality standards to maximise your chances of success.

The deadline for all submissions is SATURDAY 19TH MARCH 2022.

GENERAL RULES

1. Your abstract should be a Maximum of 350 words.
2. The presenting or lead author must register as an active participant for the full conference at the latest 14 days after acceptance of an abstract. Failure to do so may result in withdrawal of the abstract. Educational Grants are available for FREE attendance.
3. Submission can be based on any aspect of Tissue Viability including Clinical Governance, Quality Improvement, Service Development or Clinical Management project. Submissions will be blinded and peer reviewed for their suitability.
4. Blinded peer review will include an appraisal of the following: educational value of the content; methodological quality and interpretation of clinical governance and quality improvement projects (as applicable). More detailed guidance is provided below.
5. Content Headings for Clinical Governance and Quality Improvement abstracts are
 - Background
 - Methods
 - Results
 - Conclusions

Content Headings for Clinical Management or Project abstracts are

- Background of clinical issue
 - Management approach
 - Outcomes
 - Conclusions
6. Generic names must be used for all references to products. Papers containing brand names or company names in the abstract text (i.e. not in a reference at the end) will be rejected.
 7. Abstracts which have been supported by companies or authored by qualified company personnel will be considered for posters as long as:
 - The abstract meets the quality standards of the Society of Tissue Viability which are set in the section below.
 - The abstract is of genuine educational value for healthcare professionals.
 8. Abstracts which have been supported by companies or authored by company personnel will not be considered for oral presentation.

9. Oral presentations will be given during the Programme 18th-19th May. The exact day and time will be given to the successful presenter in due course.
10. The Society reserves the right to reject submissions or to request changes prior to their acceptance. In all such cases the reviewers' decision will be final.
11. While it is permissible to expand the content of an approved abstract in preparation of a poster, the structure should remain the same. Posters which break any of the rules or quality standards mentioned here will be taken down. Posters which contain product advertising through promotional product photos or branding will not be uploaded to the virtual poster platform.
12. If your abstract is accepted as a poster, the poster boards will be portrait orientation - 2m high by 1m wide.

QUALITY STANDARDS FOR POSTERS

1. Outcome measurements – these should be objective and we recommend that you use accepted instruments and tools. Comments such as “the patient felt better/more comfortable” would not be acceptable without more objective results to support your conclusion.
2. Assessment of new dressings or devices – where possible there should be at least one comparator so the differences in performance can be assessed. Small cohort studies and product evaluations suggesting enhanced product performance without a comparison group will not be accepted in this category
3. Drawing conclusions – Be careful about over stating or drawing conclusions which do not necessarily follow from your data. In such cases it is better to be tentative and make the case for further study.
4. Content headings – make sure that headings are not just included but that you give a clear description relevant to each heading.

QUALITY STANDARDS FOR ORAL PRESENTATIONS

1. All the above points apply, and in addition oral presentations should be on topics of substantial potential interest to our delegates. Accepted oral abstracts usually provide new perspectives on tissue viability presented in an innovative way and contain new information and ideas.
2. Case studies describing the use of a single product in the management of a wound will not be accepted in this category.